Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.

Showcase your company news with guaranteed exposure both in print and online Discover how AI and emerging technologies are reshaping businessand the cybersecurity strategies needed to stay… Where ...

The snow burst through the trees with no warning but a last-second whoosh of sound, a two-story wall of white and Chris Rudolph’s piercing cry: “Avalanche! Elyse!” The very thing the 16 skiers and ...